Cyanate-induced cataracts in patients with sickle-cell hemoglobinopathies.
Two young patients developed bilateral posterior subcapsular cataracts while receiving oral sodium cyanate for treatment of sickle cell hemoglobinopathy. In one of the patients, lens opacities regressed spontaneously after cyanate therapy was discontinued.
D000284:Administration, Oral; D000328:Adult; D000755:Anemia, Sickle Cell / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D002386:Cataract / Q000139:chemically induced* / Q000473:pathology; D003485:Cyanates / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007908:Lens, Crystalline / Q000473:pathology; D008297:Male; D009887:Ophthalmoscopy; D012075:Remission, Spontaneous; D013789:Thalassemia / Q000188:drug therapy; D014792:Visual Acuity / Q000187:drug effects
D003485:Cyanates